A Phase III Trial to Determine the Efficacy and Safety of Presendin in IIH
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Idiopathic intracranial hypertension (IIH) has significant associated morbidity and reduced
quality of life. There is a significant risk of visual loss and patients also typically
suffer with chronic disabling headaches.
This trial has been designed to evaluate the efficacy and safety of a new formulation of
exenatide (Presendin) in the reduction of intracranial pressure (ICP) in patients with IIH.